Meet The MKT

Massive mixed-use project to bring creative office and coworking space to the Houston Heights

The MKT expects to revolutionize the live-work-play model with everything from retail and restaurant to office and coworking space. Courtesy of The MKT

On a stroll or a spin down the Heights Hike and Bike Trail, you might not notice a complete transformation is eminent. The MKT — a mixed-use renovation and build out project — is getting ready to break ground.

The five-building, 200,000-square-foot project will bring 30 retail and restaurant concepts, and 100,000 square feet of office space together along with four acres of green space, parking, and an outdoor venue alongside 1,000 linear feet of the trail between North Shepherd Drive and Herkimer Street. The MKT name comes from the Missouri-Kansas-Texas railroad — later known as the Katy Railroad — that was transformed into the Heights Hike and Bike Trail.

MKT is a joint partnership between Houston-based Radom Capital, which is behind Heights Mercantile down the street, and Triten Real Estate Partners with capital partner, Long Wharf. The architect behind the project is Austin-based Michael Hsu Office of Architecture. Shop Companies is doing the retail leasing, and JLL's Houston office is coordinating the office leasing space.

"There's nothing in Houston that's like this that's upscale creative office space with a huge retail and restaurant component that's located on a major hike and bike trail right in the city," Russell Hodges, managing director of agency leasing at JLL, tells InnovationMap.

Ultimately, the project, which will break ground in the next 60 to 90 days, is a renovation, as the five industrial buildings that make up The MKT currently exist and were built in the '70s. The transformation will include redoing the facades of the buildings and incorporating green space.

The creative office space, which will be in three of the buildings, is doing something a little different than most office buildings in Houston. Originally, Hodges says they expected interest from TAMI tenants — which stands for technology, advertising, media, and information companies — but the interest they have had so far has been diverse.

"The project caters to the tenant that's looking for something different — looking for, honestly for lack of a better word, cool space," Hodges says. "Someone looking for something to help differentiate their business to leverage their office space to recruit and retain talent."

Another unexpected interested party — coworking tenants. Hodges says the project could house anywhere from 20,000 to 50,000 square feet of coworking space if the right coworking operator comes around.

"I don't think we were necessarily looking for coworking, per say," Hodges says. "But, we've had significant interest from coworking operators. Based on that level of interest, we think that there's demand for coworking in the area. We're looking for the right operator who's brand aligns with the brand of the project. I don't think that's every coworking brand, necessarily."

The team behind The MKT are also planning a second phase of the project for a large space just east of phase one. That concept has yet to be designed, and there aren't any specifics currently available.

Big picture

Courtesy of The MKT

On the project's website, this rendering can be interacted with to see 3D designs and before and after shots.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News